Andrea Moreno-Manuel1, Sotiris Ouzounis2, Marius Eidsaa3

  • 1Cancer Heterogeneity and Immunomics (CHI) Group, University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.

概括

新抗原,来自瘤的突变,是癌症免疫治疗的关键标. 计算工具正在进步,以识别和优先考虑这些新抗原以进行个性化治疗.